NeuroSense Therapeutics Statistics
Total Valuation
NRSN has a market cap or net worth of $24.34 million. The enterprise value is $22.78 million.
Important Dates
The next estimated earnings date is Tuesday, November 26, 2024, before market open.
| Earnings Date | Nov 26, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NRSN has 19.47 million shares outstanding. The number of shares has increased by 36.48% in one year.
| Current Share Class | 19.47M |
| Shares Outstanding | 19.47M |
| Shares Change (YoY) | +36.48% |
| Shares Change (QoQ) | +17.77% |
| Owned by Insiders (%) | 25.43% |
| Owned by Institutions (%) | 0.51% |
| Float | 14.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.46
| Current Ratio | 0.46 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -418.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -150.79% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$544,333 |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +144.44% in the last 52 weeks. The beta is 1.56, so NRSN's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | +144.44% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.21 |
| Relative Strength Index (RSI) | 51.08 |
| Average Volume (20 Days) | 220,115 |
Short Selling Information
The latest short interest is 235,717, so 1.21% of the outstanding shares have been sold short.
| Short Interest | 235,717 |
| Short Previous Month | 307,426 |
| Short % of Shares Out | 1.21% |
| Short % of Float | 1.62% |
| Short Ratio (days to cover) | 1.52 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.71M |
| Pretax Income | -10.11M |
| Net Income | -9.80M |
| EBITDA | -11.69M |
| EBIT | -11.71M |
| Earnings Per Share (EPS) | -$0.61 |
Full Income StatementBalance Sheet
The company has $1.21 million in cash and $36,000 in debt, giving a net cash position of $1.17 million or $0.06 per share.
| Cash & Cash Equivalents | 1.21M |
| Total Debt | 36,000 |
| Net Cash | 1.17M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | -1.70M |
| Book Value Per Share | -0.09 |
| Working Capital | -1.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.20 million and capital expenditures -$7,000, giving a free cash flow of -$10.21 million.
| Operating Cash Flow | -10.20M |
| Capital Expenditures | -7,000 |
| Free Cash Flow | -10.21M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |